Introduction {#s1}
============

Tendons connect muscle to bone and function to transmit muscle forces to the skeleton. Tendon function is enabled by a specialized extracellular matrix predominantly composed of highly aligned type I collagen fibrils ([@bib45]). Although healthy tendon can normally resist high mechanical loads, mechanical properties are permanently impaired after injury due to its minimally regenerative potential ([@bib45]). This loss of function can lead to chronic pain, decreased quality of life, and increased risk of re-rupture. Current treatment options remain limited and there are almost no cell or biological treatments to improve tendon repair or induce regeneration.

To date, the majority of injury models to study tendon healing result in scar-mediated healing since adult tendon does not regenerate ([@bib2]; [@bib16]; [@bib15]; [@bib21]; [@bib23]; [@bib24]; [@bib32]). Although a few groups showed successful tendon regeneration in model systems such as fetal sheep and MRL/MpJ mice, genetic manipulation is relatively challenging in these systems ([@bib4]; [@bib37]). To overcome these limitations, we previously established a model of tendon regeneration in neonatal mice, that can be directly compared to fibrotic tendon healing in adult mice within the same genetic background ([@bib21]). Using lineage tracing, we found that neonatal tendon regeneration is driven by tenocyte proliferation, recruitment, and differentiation leading to full functional restoration. In contrast, adult tendon healing is defined by the persistence of aSMA+ cells, absence of tenocyte proliferation or recruitment, abnormal differentiation into cartilaginous cells, and loss of functional tendon properties. Having identified cellular processes distinguishing neonatal and adult tendon healing, we now focus on the molecular pathways that regulate neonatal tendon regeneration.

Although FGF signaling was first established in chick tendon development ([@bib7]), the TGFβ pathway subsequently emerged as the most important signaling pathway identified for mammalian tendon formation ([@bib20]; [@bib25]; [@bib39]). Members of the TGFβ superfamily of growth factors signal through type II receptors, which then dimerize with type I receptors. The type I receptor then phosphorylates intracellular Smad transcription factors that complex with the co-Smad, SMAD4, to change transcriptional programs ([@bib43]). In mouse embryos, TGFβ ligands are expressed by tendon cells and genetic deletion of the TGFβ type II receptor (TβR2) or the TGFβ ligands result in a total absence of tendons ([@bib20]; [@bib25]; [@bib39]). TGFβs also induce expression of the tendon transcription factor, *Scleraxis* (*Scx*), in different experimental systems including embryonic limb explants, mesenchymal stem cells, and tendon-derived cells ([@bib8]; [@bib31]; [@bib39]).

In addition to its essential role in tendon development and tendon cell differentiation, TGFβ is also a known inducer of fibrotic scar formation in diverse tissues, including adult tendon ([@bib23]; [@bib24]; [@bib44]). TGFβ is well established as a driver of myofibroblast differentiation ([@bib6]; [@bib14]) and excessive release of TGFβ ligand after injury can also induce tenocyte death ([@bib31]). Given these contradictory roles of TGFβ signaling in both tendon differentiation and scar formation, it is unclear whether TGFβ signaling enacts a positive or negative response in the context of tendon regeneration. To determine the requirement for TGFβ signaling in neonatal tendon regeneration, we used pharmacological TGFβ inhibition and genetic deletion experiments. We identified a role for canonical TGFβ signaling in promoting functional regeneration of neonatal tendon and recruitment of tenogenic cells derived from both *Scx* and non-*Scx* lineages.

Results {#s2}
=======

TGFβ signaling is activated after neonatal injury {#s2-1}
-------------------------------------------------

To determine whether TGFβ signaling is activated after neonatal injury, we measured gene expression of the TGFβ type II receptor (*Tgfbr2*) and the isoforms *Tgfb1*, *Tgfb2*, and *Tgfb3* at day (d) 3, d7, d14, and d28 post-injury by qPCR. *Tgfbr2 *was expressed at all time points after injury and upregulated in injured tendons compared to uninjured controls at d7 and d28 (p\<0.01) ([Figure 1A](#fig1){ref-type="fig"}). *Tgfb1 *and *Tgfb2 *expression levels were transiently upregulated at alternating time points; however, overall expression levels were quite low for *Tgfb2* expression (several fold lower than *Tgfb1* and *Tgfb3*), suggesting a relatively minor role in regeneration for this ligand. By contrast, *Tgfb3* expression was increased at all time points relative to control ([Figure 1A](#fig1){ref-type="fig"}). Consistent with the gene expression analysis, western blot analysis showed Smad2/3 phosphorylation (pSmad2/3) in injured tendons at d14, suggesting activation of canonical TGFβ signaling ([Figure 1B](#fig1){ref-type="fig"}). Analysis of active and total TGFB1 ligand by ELISA showed no change in the amount of active TGFB1 with injury, but a significant increase in total TGFB1 ([Figure 1C](#fig1){ref-type="fig"}). Collectively, these results suggest activation of TGFβ signaling in neonatal tendon regeneration.

![TGFβ signaling is activated after neonatal tendon injury.\
(**A**) Gene expression in control and injured tendons at d3, d7, d14, and d28 post-injury by qPCR showed upregulation of *Tgfbr2* receptor and *Tgfb1*, *Tgfb2*, *Tgfb3* ligands. Expression levels were normalized to *Gapdh* using a standard curve method (n = 5--7 mice). (**B**) Western blot of control and injured tendons at d14 showed Smad2/3 phosphorylation after injury indicative of active TGFβ signaling (3 tendons per sample, n = 3 samples). (**C**) ELISA detection of active and total TGFB1 protein at d14 shows no change in active TGFB1 and increased total TGFB1 with injury (3 tendons per sample, n = 3 samples). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-51779-fig1){#fig1}

TGFβ signaling is required for functional regeneration {#s2-2}
------------------------------------------------------

To test the requirement for TGFβ signaling in functional neonatal tendon regeneration ([Figure 2](#fig2){ref-type="fig"}), we inhibited TGFβ signaling for 14 days after injury using the well-established small molecule inhibitor SB-431542, which targets the TGFβ type I receptors ALK 4/5/7 ([@bib3]; [@bib9]; [@bib22]; [@bib29]; [@bib34]; [@bib36]; [@bib40]; [@bib41]; [@bib42]). Analysis of pSmad2/3 by western blotting showed a significant decrease with SB-431542 treatment when normalized to contralateral control tendons ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In contrast, phospho-p38, which is a Smad-independent mediator of TGFβ signaling was not affected ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Neonatal mice treated with the SB-431542 showed no adverse effects on growth compared to carrier-treated mice and tendons appeared grossly normal ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

![TGFβ signaling is required for functional recovery.\
Gait analysis at (**A**) d14 and (**B**) d28 showed impaired % brake stride and % propel stride after injury with SB-431542 treatment. (**C, D**) Tensile testing at d28 revealed reduced stiffness and max force with SB-431542 treatment. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (n = 8--10 mice).](elife-51779-fig2){#fig2}

To determine the role of TGFβ signaling in functional healing, we first analyzed the gait parameters % brake and % propel, which are highly associated with Achilles tendon function ([@bib21]). Carrier-treated mice fully recovered % brake and % propel by d14, consistent with functional regeneration ([Figure 2A](#fig2){ref-type="fig"}). By contrast, both % brake and % propel were impaired relative to the contralateral control limb with SB-431542 treatment. We also observed a significant decrease in % propel stride relative to the injured limb of carrier-treated animals. Defects in whole limb gait persisted until d28 for both parameters despite cessation of inhibitor treatment at d14 ([Figure 2B](#fig2){ref-type="fig"}).

To determine the mechanical properties of the healing tissue directly, we performed tensile testing of the tendons at d28. Although mechanical properties in uninjured control tendons were not significantly different with SB-431542 treatment, we observed a reduction in stiffness and max force of injured SB-431542-treated tendons relative to carrier ([Figure 2C and D](#fig2){ref-type="fig"}). Taken together, these data showed that TGFβ signaling in the first 14 days after injury is required for functional tendon regeneration.

TGFβ signaling in neonatal tenocytes is required for cell recruitment after injury {#s2-3}
----------------------------------------------------------------------------------

We previously found that *Scx*-lineage (Scx^lin^) tenocyte proliferation, recruitment, and differentiation are unique features of the neonatal regenerative response that are not observed during adult healing ([@bib21]). To determine the cellular basis for the functional deficits observed with TGFβ inhibition, we next assessed whether tenocyte recruitment is affected by TGFβ inhibition using the *Scx-CreERT2* mouse ([Figure 3](#fig3){ref-type="fig"}). Differentiated *Scx*-expressing tenocytes were labeled by tamoxifen prior to injury and traced during regeneration with SB-431542 inhibition. Analysis of non-tamoxifen treated *Scx-CreERT2*; ROSA-Ai14 mice affirmed the absence of leakiness by the Cre-allele since TdTomato+ cells were not observed even at 1 year of age ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In carrier-treated, tamoxifen-injected mice, whole mount imaging of hind limbs showed Scx^lin^ cells (TdTomato+) occupying the gap space between the original Achilles tendon stubs at d14 after transection ([Figure 3A](#fig3){ref-type="fig"}), while little TdTomato signal was detected in SB-431542-treated limbs ([Figure 3B](#fig3){ref-type="fig"}). Quantification of transverse sections taken from the midsubstance regions confirmed reduced Scx^lin^ tenocyte numbers with TGFβ signaling inhibition ([Figure 3C and D](#fig3){ref-type="fig"}). Interestingly, when Scx^lin^ tenocytes were normalized to total DAPI-positive cells, this difference was abolished. Quantification of total number of cells confirmed decreased cell number with SB-431542 treatment, suggesting a cell recruitment or cell proliferation defect (1119 ± 252 carrier vs 637 ± 170 SB-431542, p=0.01).

![TGFβ signaling is required for tenocyte recruitment at d14.\
(**A, B**) Whole mount images of control and injured limbs in carrier-treated and SB-431542-treated *Scx-CreERT2*; ROSA-Ai14 mice at d14. (**C**) Transverse sections through the neotendon (yellow boxes) near the mid-substance and (**D**) quantification showed reduced Scx^lin^, TdTomato+ cell recruitment with SB-431542 treatment, but no difference when normalized to total cells (n = 4--5 mice). (**E, F**) Whole mount images of control and injured limbs in wild type *Scx-CreERT2*; ROSA-Ai14 and TGFBR2^Scx^; ROSA-Ai14 mice. (**G**) Transverse sections through the neotendon near the mid-substance and (**H**) quantification showed reduced Scx^lin^, TdTomato+ cell recruitment in TGFBR2^Scx^ mutants (n = 3 mice). \*p\<0.05, n.s. indicates p\>0.05. Scale bars: 100 µm.](elife-51779-fig3){#fig3}

Since SB-431542 treatment targets all cells and we observed reduced total cell number in the neotendon with TGFβ signaling inhibition, we next tested whether neonatal tenocytes directly required TGFβ signaling for their recruitment. We therefore deleted *Tgfbr2* using *Scx-CreERT2* prior to injury and labeled mutant cells by TdTomato (*Tgfbr2^f/f^; Scx-CreERT2*; ROSA-Ai14; referred to here as TGFBR2^Scx^). Since TGFβ signaling is mediated by a single type II receptor (TGFBR2), all TGFβ signaling is abolished with deletion of this receptor. Antibody staining against TGFBR2 confirmed deletion of the receptor in the majority of Scx^lin^ cells in TGFBR2^Scx^ injured tendon stubs at d14 ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Consistent with our inhibitor studies, few Scx^lin^ tenocytes were detected in the neotendon of TGFBR2^Scx^ mutant tendons compared to *Scx-CreERT2* wild type tendons at d14 post-injury ([Figure 3F--H](#fig3){ref-type="fig"}). This difference was maintained when Scx^lin^ cells were normalized to total DAPI-positive cells ([Figure 3H](#fig3){ref-type="fig"}), since quantification of total cell number showed no difference between wild type and mutant tendon (928 ± 359 WT vs 976 ± 484 TGFBR2^Scx^, p=0.9). These data suggest that TGFβ signaling is required for tenocyte recruitment after neonatal injury, rather than it being a consequence of TGFβ inhibition on other cells. Our data further show that while wild type, non-Scx^lin^ cells are able to compensate for the absence of TGFBR2^Scx^ knockout Scx^lin^ cells, this compensation does not occur when TGFβ signaling is systemically inhibited in all cells.

TGFβ signaling is required for tenocyte migration but not proliferation {#s2-4}
-----------------------------------------------------------------------

We hypothesized that the absence of Scx^lin^ cell recruitment at d14 with TGFβ inhibition may be due to a defect in cell proliferation at an earlier time point. In a previous study, we showed intense Scx^lin^ tenocyte proliferation that was localized at the cut site of tendon stubs at d3. To test this hypothesis, we collected *Scx-CreERT2*-labeled limbs at d3 post-injury with SB-431542 treatment as well as TGFBR2^Scx^ deletion. Consistent with previous findings, transverse sections through the midsubstance gap space confirmed that Scx^lin^ cells were not detectable at d3 after injury for any condition (not shown). EdU staining of proliferating cells at the cut site of the tendon stubs showed comparable numbers of proliferating Scx^lin^ tenocytes between carrier-treated and SB-431542-treated mice after injury ([Figure 4A--C](#fig4){ref-type="fig"}). Similarly, no differences were detected between injured, wild type and TGFBR2^Scx^ mutants ([Figure 4D--F](#fig4){ref-type="fig"}). However, total cell proliferation (Scx^lin^ and non-Scx^lin^) was decreased with SB-431542-treatment (p=0.07), while no difference in total cell proliferation was detected in TGFBR2^Scx^ mutants ([Figure 4C and F](#fig4){ref-type="fig"}). At this time point, tenocyte proliferation in uninjured control Achilles tendons was almost undetectable (0--1 EdU+/Scx^lin^+ cell per section) and was unaffected by SB-431542 treatment or TGFBR2^Scx^ deletion ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These data suggest that reduced cell number at d14 with inhibitor treatment may be due in part to reduced proliferation of non-Scx^lin^ cells.

![TGFβ signaling is not required for tenocyte proliferation.\
Transverse sections through the cut site of (**A, A', A'**) carrier-treated injured tendon or (**B, B', B'**) SB-431542-treated injured tendon stained for EdU and counterstained with DAPI. (**C**) Quantification of EdU and Scx^lin^ overlays showed no difference in Scx^lin^ cell proliferation after injury with TGFβ inhibition, while % total proliferating cells was decreased with SB-431542 treatment (n = 3 mice). Transverse sections through the cut site of (**D, D', D'**) wild type injured tendon or (**E, E', E'**) TGFBR2^Scx^ injured tendon stained for EdU and counterstained with DAPI. (**F**) Quantification of EdU and Scx^lin^ overlays show no difference in Scx^lin^ cell proliferation or total cell proliferation after injury with TGFBR2^Scx^ deletion (n = 3 mice). A', B', D', E' are enlarged images from yellow boxed regions shown in A', B', C', D'. White arrows indicate EdU+, Scx^lin^ cells. n.s. indicates p\>0.1. Scale bars: 100 µm.](elife-51779-fig4){#fig4}

Since proliferation of Scx^lin^ cells was not affected at d3, we next determined whether TGFβ signaling may be required for tenocyte migration. In vitro scratch assays in tenocyte monolayers were used to induce cell migration ([Figure 5A](#fig5){ref-type="fig"}). Tenocytes in DMEM alone did not migrate at any time point. Differences in wound closure were not observed between DMEM and DMEM+FBS until 12 hr. In contrast, addition of TGFB1 significantly enhanced cell migration, and differences in wound closure were detected as early as 4 hr after scratching with nearly full closure achieved by 8 hr ([Figure 5A](#fig5){ref-type="fig"}). To confirm that accelerated migration occurred in Scx^lin^ cells, we labeled tendons of *Scx-CreERT2* mice at P2 and P3, and isolated cells at P7 from non-injured tendons. We observed enhanced Scx^lin^ cell migration with TGFB1 treatment ([Figure 5B](#fig5){ref-type="fig"}). Quantification of Scx^lin^ proliferating cells detected by EdU showed minimal proliferation with no differences detected across treatment groups ([Figure 5B](#fig5){ref-type="fig"}). EdU quantification for non-Scx^lin^ cells also showed no difference (2.89 ± 1.24% DMEM vs 3.46 ± 2.01% DMEM+FBS vs 3.26 ± 1.23% DMEM+FBS+TGFB1, p=0.8).

![TGFβ enhances neonatal tenocyte migration in vitro.\
(**A**) Phase contrast images and (**B**) quantification of in vitro wound assay show accelerated closure with TGFB1 supplementation relative to DMEM and DMEM+FBS conditions (n = 6). (**C**) Phase contrast and (**D**) fluorescence images show enhanced (**E**) Scx^lin^ cell migration with TGFB1 treatment. (**F**) No difference was observed in cell proliferation at 8 hr (n = 5--6). \*p\<0.05, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. n.s. indicates p\>0.1.](elife-51779-fig5){#fig5}

Collectively, these results suggest that TGFβ signaling is required for recruitment of neonatal tenocytes after injury, and that tenocyte recruitment requires active cell migration rather than expansion through cell proliferation. In contrast, proliferation of non-Scx^lin^ cells at d3 may depend on TGFβ signaling.

Increased TGFβ ligand production in injured tendon depends on TGFβ signaling {#s2-5}
----------------------------------------------------------------------------

Although Scx^lin^ cells are not present in the gap space at d3, the region is not devoid of cells. At this time, we observed early accumulation of αSMA+ cells that are not derived from the Scx^lin^ ([@bib21]). Surprisingly, immunostaining for αSMA revealed that recruitment of αSMA+ cells at d3 was not affected by TGFβ inhibition or *Tgfbr2* deletion ([Figure 6A,B](#fig6){ref-type="fig"}). Transverse sections through the midsubstance gap space also confirmed that Scx^lin^ cells were not yet detectable at d3 in any condition (not shown). The presence of αSMA+ cells within the gap space prior to Scx^lin^ cell recruitment suggested that these cells may be a source of TGFβ ligands that signal to tenocytes for migration. Immunostaining for all three TGFβ isoforms showed comparable levels of signal between gap space of injured tendons and midsubstance of control tendons ([Figure 7A,B](#fig7){ref-type="fig"}). We therefore considered the possibility that ligand production may be regulated by TGFβ signaling and that impaired recruitment is due to reduction of TGFβ ligands with SB-431542 inhibition. However, immunostaining for TGFβ ligands showed equivalent staining intensity within the injury gap space of carrier- and SB-431542-treated limbs ([Figure 7A,B](#fig7){ref-type="fig"}). Differences were only observed in injured tendons at the cut site. We found increased ligand staining at the cut site of carrier-treated injured tendons relative to uninjured control, but this increase did not occur with SB-431542 inhibition ([Figure 7C,D](#fig7){ref-type="fig"}). Since the antibody does not distinguish between latent and active TGFβ ligands, we also quantified active TGFB1 protein by ELISA, but no differences were detected in whole tendon lysate by d14, regardless of injury or treatment ([Figure 7E](#fig7){ref-type="fig"}). These data suggest that TGFβ signaling is required for upregulation of TGFβ ligands with injury at d3, and that this is likely autonomously regulated in neonatal tenocytes.

![Recruitment of αSMA+ cells is not affected by TGFβ inhibition or TGFBR2^Scx^ deletion.\
Transverse sections through the gap space at d3 showed abundant αSMA+ cells with (**A**) SB-431542 treatment or (**B**) TGFBR2^Scx^ deletion at levels comparable to carrier-treated or wild type. Yellow dashed outlines highlight gap area formerly occupied by the Achilles tendon.](elife-51779-fig6){#fig6}

![TGFβ ligand synthesis after injury is regulated by TGFβ signaling.\
(**A**) Transverse sections through the midsubstance tendon and neotendon regions at d3 immunostained with antibody against all three TGFβ isoforms. (**B**) Quantification of intensity levels show no difference in staining between groups. (**C**) Transverse sections through the tendon cut site regions at d3 immunostained with antibody against all three TGFβ isoforms. (**D**) Quantification of intensity levels show increased TGFβ ligands after injury in carrier-treated tendons that is no longer observed with SB-431542 treatment. Yellow dashed outlines indicate region of interest quantified. (**E**) TGFB1 protein quantification by ELISA showed no differences with injury or SB-431542 treatment at d14. \*p\<0.05 \*\*p\<0.01 n.s. indicates p\>0.1. Scale bar: 100 µm.](elife-51779-fig7){#fig7}

Non-Scx^lin^ tenogenic cells also contribute to neotendon formation {#s2-6}
-------------------------------------------------------------------

Although αSMA+ cells are present at d3, immunostaining generally showed reduced αSMA+ cells by d14. However, more αSMA+ staining was observed with SB-431542 treatment relative to carrier ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This may suggest that αSMA+ cells persist longer with TGFβ inhibition or maintain a progenitor or myofibroblastic phenotype. Since previous studies using *Acta2-CreERT2* (*Acta2* is the gene for αSMA) showed that adult αSMA-lineage (αSMA^lin^) cells of the paratenon surrounding tendons are resident progenitor cells for tendon ([@bib15]), we hypothesized that αSMA+ cells recruited into the gap space (which are not Scx^lin^ at d3) may differentiate toward the tendon lineage and thereby turn off αSMA. Analysis of *Scx-GFP* expression in carrier-treated injured limbs indeed showed a population of non-Scx^lin^, *Scx-GFP*+ cells within the neotendon ([Figure 8A,B](#fig8){ref-type="fig"}). Comparison to contralateral non-injured controls indicated that incomplete recombination of Scx^lin^ cells does not explain this phenomenon since recombination efficiency is \~96.4% in control tendons. Quantification of the non-Scx^lin^ *Scx-GFP*+ (*Scx-GFP* only) population showed fewer *Scx-GFP*-only cells in the neotendon after injury in SB-431542-treated mice ([Figure 8C--E](#fig8){ref-type="fig"}). There was a proportional decrease in DAPI+ cells, indicating that the reduction in *Scx-GFP* only cells was probably not due to failure of cells within the gap space to differentiate. Analysis of TGFBR2^Scx^ mutants at d28 also showed the presence of *Scx-GFP*-only cells when Scx^lin^ cells were minimally recruited ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

![A population of *Scx-GFP*+, non-Scx^lin^ cells are recruited after neonatal tendon injury.\
Transverse sections through the neotendon of control and injured limbs in (**A, B**) carrier-treated and (**C, D**) SB-431542-treated *Scx-CreERT2*; ROSA-Ai14; *Scx-GFP* mice. (**E, F**) Quantification of non-Scx^lin^, *Scx-GFP*+ cells show reduction in cell number with SB-431542 treatment but not when normalized to total DAPI+ cells (n = 3 mice). \*p\<0.05. n.s. indicates p\>0.1. Scalebar: 100 µm.](elife-51779-fig8){#fig8}

To determine whether these non-Scx^lin^, *Scx-GFP*+ cells were derived from αSMA+ cells, we labeled cells by tamoxifen administration at P2, P3 in transgenic *Acta2-CreERT2* mice. Analysis of transverse cryosections at P5 showed an unexpected amount of recombination in *Scx-GFP* tenocytes ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). Immunostaining for αSMA in control, uninjured tendons confirmed that neonatal tenocytes normally do not express αSMA. To determine recruitment and differentiation of αSMA^lin^ cells, we labeled cells at P2, P3, injured tendons at P5 and harvested limbs at d14. Despite minimal αSMA immunostaining at d14 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), we detected αSMA^lin^ cells (TdTomato+) within the neotendon and the majority of αSMA^lin^ cells appeared *Scx-GFP*-negative ([Figure 8---figure supplement 3](#fig8s3){ref-type="fig"}). In addition to TdTomato+/*Scx-GFP*- cells, we also identified TdTomato+/*Scx-GFP*+ cells and *Scx-GFP*+ cells in both carrier and SB-431542 treated neotendons ([Figure 8---figure supplement 3](#fig8s3){ref-type="fig"}).

Immunostaining results for αSMA at d14 suggested persistence of a progenitor phenotype with systemic TGFβ inhibition ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To test whether tendon cell differentiation is affected, we determined tendon marker gene expression by real time qPCR at d3 and d14 post-injury. At d3, the tendon markers *Scx*, *Mkx,* and *Tnmd* were decreased in carrier-treated injured tendons compared to their contralateral uninjured controls ([Figure 9A](#fig9){ref-type="fig"}). Interestingly, inhibition of TGFβ signaling with SB-431542 also decreased tendon marker gene expression in uninjured control tendons relative to carrier controls. By d14, tendon marker gene expression was unaltered regardless of treatment or injury ([Figure 9B](#fig9){ref-type="fig"}). Expression levels of *Sox9* and *Acta2* were not different across experimental conditions at either time point ([Figure 9A,B](#fig9){ref-type="fig"}). Collectively, these data indicate that despite defects in tenogenic cell recruitment, tendon marker gene expression and by extension tendon cell differentiation after injury was largely not affected by inhibition of TGFβ signaling.

![Tendon marker gene expression is not altered by TGFβ signaling inhibition at d14 post-injury.\
Real time qPCR analysis of tendons harvested at (**A**) d3 and (**B**) d14 from carrier-treated and SB-431542-treated animals (n = 4--6 mice). Tendon genes were decreased after injury in carrier-treated mice but not with SB-431542 treatment at d3. Differences were no longer detected by d14. *Sox9* and *Acta2* were not significantly different at either time point. \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001.](elife-51779-fig9){#fig9}

Discussion {#s3}
==========

In this study, we identified TGFβ-dependent and TGFβ-independent processes contributing to neonatal tendon regeneration. We found that early proliferation of Scx^lin^ tenocytes and activation of aSMA+ cells do not depend on TGFβ signaling. However, proliferation of non-Scx^lin^ cells, subsequent recruitment of tenogenic cells (from Scx^lin^ and non-Scx^lin^ sources), and functional restoration depend on TGFβ signaling ([Figure 10](#fig10){ref-type="fig"}). TGFβ signaling is a known regulator of many cellular processes, including cell proliferation, migration, and differentiation ([@bib43]). In tendon, TGFβ signaling is essential for embryonic tendon development as well as for the induction and maintenance of tendon cell fate ([@bib39]). However, after injury, TGFβ signaling is also known as a driver for fibrotic, scar-mediated healing and excessive TGFβ signaling results in tenocyte apoptosis ([@bib13]; [@bib23]). In the context of tendon regeneration, it was therefore unclear whether TGFβ would be required for tendon differentiation or whether activation of TGFβ would drive fibrotic responses. Using our previously established model of neonatal tendon regeneration, we show here that TGFβ signaling is induced after injury and is required for the recruitment of neonatal tenocytes to the injury site. Since tenocyte proliferation after injury was not affected by inhibition of TGFβ signaling, we propose that tenocyte-mediated regeneration requires active migration of cells to bridge the gap space. This is further supported by in vitro data showing enhanced migration of neonatal tenocytes in the presence of TGFβ ligand and is consistent with several studies for other cell types ([@bib43]).

![Requirement for TGFβ signaling in neonatal tendon regeneration.\
Schematic depiction of conceptual model of the TGFβ-dependent and TGFβ-independent cellular processes during neonatal tendon regeneration. While tenocyte proliferation and αSMA cell recruitment at d3 occur independently of TGFβ signaling, subsequent tenogenic cell recruitment and functional tendon tissue restoration requires TGFβ signaling.](elife-51779-fig10){#fig10}

In addition to tenocytes, we also identified a second population of non-Scx^lin^, *Scx-GFP*+ cells that are recruited to the gap space. Inhibition of TGFβ signaling also resulted in reduced numbers of these cells. One potential source of these cells may be the epitenon as it was previously proposed that tendon stem/progenitor cells reside in epitenon ([@bib16]; [@bib15]; [@bib18]; [@bib33]; [@bib35]). Although lineage tracing with *Acta2-CreERT2* showed restricted labeling in the epitenon/paratenon in adults ([@bib16]), we found considerable labeling in tenocytes at neonatal stages. After injury, αSMA^lin^ cells were recruited into the neotendon, suggesting that this may be the source of non-Scx^lin^, *Scx-GFP* cells. However, not all of the *Scx-GFP* cells in this line were derived from αSMA^lin^ cells; therefore, the possibility of additional sources of tenogenic cells cannot be excluded. Alternatively, since *Acta2-CreERT2* labels only a sub-population of uninjured tenocyes, it may be that *Scx-GFP*-only cells in these mice are derived from the Scx^lin^, non-αSMA^lin^ population. Double labeling for αSMA^lin^ and Scx^lin^ cells would be required to test this hypothesis; however, this is not currently possible using existing genetic tools. Other sources of tenogenic cells include tendon-associated vasculature, as CD146+ pericytes have been identified near tendon ([@bib28]). Since *Scx-GFP* may also be more broadly expressed compared to true *Scx* expression ([@bib5]; [@bib38]), the non-Scx^lin^/*Scx-GFP* and non-αSMA^lin^/*Scx-GFP* populations detected may also be a limitation of the transgenic reporter and not represent novel tenogenic cell populations. These issues can be addressed by using single cell RNASeq of sorted Scx^lin^ and αSMA^lin^ populations in future studies.

Unlike Scx^lin^ cells, αSMA^lin^ cells were present in the neotendon at d14 with SB-431542 treatment, consistent with immunostaining results showing considerable presence of αSMA+ cells at d3. However, quantitative measurements are required to determine whether proliferation or recruitment of these cells is affected by SB-431542 treatment. In addition to the αSMA^lin^/*Scx-GFP*+ cells occupying the neotendon at d14, we also identified αSMA^lin^/*Scx-GFP*- cells. These cells were largely negative for αSMA immunostaining at this timepoint, yet did not adopt a tenogenic phenotype. The role of this population in tendon regeneration is unclear, but they may function to support tenogenic cells, undergo tenogenesis themselves, or also adopt a fibrotic phenotype. Furthermore, it is unclear whether the αSMA^lin^ cells in the gap space at d3 are the same ones observed in the neotendon at d14, or whether they represent a second wave of cell recruitment at later stages of the healing response. Additional experiments with quantitative measurements, temporal labeling, and localized ablation can be carried out in future studies to fully elucidate the dynamics of the αSMA^lin^ populations, their interaction with the Scx^lin^ population, and their roles in tendon regeneration and fibrosis. Despite impaired recruitment of tenogenic cells after TGFβ signaling inhibition, the expression of tenogenic markers *Scx*, *Tnmd*, and *Mkx* were not different at d14. Identifying additional markers for tendon cell fate is the focus of ongoing studies.

We identified a potential source of TGFβ ligands in cells within the gap space, which may drive directional migration of the tenocytes from the stubs. After injury, there was an increase in TGFβ ligands in the tendon stub, which was suppressed by small molecule inhibition of TGFβ signaling. This suggests that initiation of TGFβ signaling results in positive feedback in tenocytes. We also observed a requirement for proliferation and recruitment of non-Scx^lin^ cells, but only with SB-431542 treatment and not in the TGFBR2^Scx^ mutant (which only targets TGFβ signaling in Scx^lin^ cells). This suggests that in the absence of Scx^lin^ cell recruitment, there is compensatory proliferation or recruitment of non-Scx^lin^ cells that also depends on TGFβ signaling. Other sources of TGFβs may be immune cells, which are known to secrete TGFβs. Of the three TGFβ isoforms, gene expression data suggested that the primary ligands driving neonatal regeneration may be TGFβs 1 and 3. Although *Tgfb1* showed bimodal upregulation pattern, *Tgfb3* was consistently upregulated after injury. Analysis of TGFB1 protein at d14 surprisingly showed a large change of total TGFB1 only, with no change in active TGFB1. TGFβs are typically secreted in a latent form bound to LTBPs in the extracellular matrix and release of TGFβs to its active form can be induced by proteases or mechanically (such as with transection injury) ([@bib31]). It is generally thought that ligand signaling can only occur with release of TGFβs from LTBP. However, recent studies using cryo-EM suggest that TGFβ activation can also occur without release from LTBP. This mechanism depends on interaction with the integrin αvβ8 ([@bib10]). Alternatively, it is also possible that signaling is mostly mediated by active TGFB3, which was not measured (validated ELISA kits to specifically detect mouse TGFB3 in tissue lysates are currently not available). During embryonic development, *Tgfb2* and *Tgfb3* are expressed in tendons and allelic deletion of these ligands results in increasing loss of tendons ([@bib25]; [@bib39]); in the context of injury, *Tgfb3* is expressed during regenerative fetal tendon healing in sheep while TGFB1 is associated with fibrotic adult tendon healing ([@bib4]; [@bib24]). Although this supports the notion that TGFβs 2 and 3 are pro-tenogenic relative to TGFB1, it is unclear whether the individual ligands actually can activate distinct healing or tenogenic responses. Additional research must therefore be carried out to elucidate their activities.

Although adult tendon healing was not determined in this study, it is well established that TGFβ signaling is elevated after adult injury and results in fibrotic scar formation ([@bib27]). Inhibition of TGFβ signaling, either with neutralizing antibodies or via *Smad3^-/-^* deletion attenuates fibrosis but fails to regenerate tendon structure or function ([@bib23]; [@bib24]). We previously showed that adult tenocytes are largely quiescent after full transection injury with minimal cell proliferation or recruitment. The distinctive response of neonatal vs adult tenocytes to TGFβ may reflect differences in intrinsic potential (for example adult tenocytes are post-mitotic) or the activation of other signaling pathways that may interact with or modify TGFβ signaling. In addition to Smad signaling, TGFβs can also activate a number of non-Smad pathways ([@bib47]); there may be differences in downstream signaling between neonatal and adult tenocytes. Using an in vitro engineered tendon model, we previously showed that the tenogenic outcomes of TGFβ signaling did not depend on *Smad4* ([@bib11]). Whether this finding is applicable in the context of in vivo injury remains to be determined.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                                                                  Source or\                                                                                Identifiers                                                                        Additional\
  (species) or\                                                                                                                  reference                                                                                                                                                                    information
  resource                                                                                                                                                                                                                                                                                                    
  --------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- -------------
  Genetic reagent (*M. musculus*)   Tg(Scx-GFP)1Stzr\                                                                            Ronen Schweitzer\                                                                         RRID:[MGI:3717419](https://scicrunch.org/resolver/MGI:3717419)                     
                                    (ScxGFP)                                                                                     ([@bib38])                                                                                                                                                                   

  Genetic reagent (*M. musculus*)   Scx-CreERT2                                                                                  Ronen Schweitzer                                                                          N/A                                                                                

  Genetic reagent (*M. musculus*)   [Tg(Acta2-cre/ERT2)1Ikal](http://www.informatics.jax.org/allele/key/827618)(Acta2-CreERT2)   Ivo Kalajzic\                                                                             RRID:[MGI:5461154](https://scicrunch.org/resolver/MGI:5461154)                     
                                                                                                                                 ([@bib17])                                                                                                                                                                   

  Genetic reagent (*M. musculus*)   Gt(ROSA)26Sor^tm14(CAG-tdTomato)Hze^\                                                        Jackson Labs\                                                                             Stock: 007908\                                                                     
                                    (ROSA-Ai14)                                                                                  ([@bib30])                                                                                RRID:[MGI:3809524](https://scicrunch.org/resolver/MGI:3809524)                     

  Genetic reagent (*M. musculus*)   Tgfbr2^tm1.1Hlm^\                                                                            Harold Moses\                                                                             RRID:[MGI:2384512](https://scicrunch.org/resolver/MGI:2384512)                     
                                    (Tgfbr2^f/f^)                                                                                ([@bib12])                                                                                                                                                                   

  Chemical compound, drug           SB-431542                                                                                    Stemgent                                                                                  Cat. \# 04-0010-10                                                                 

  Antibody                          Anti-alpha-SMA (mouse monoclonal)                                                            Sigma-Aldrich                                                                             Cat. \# A5228\                                                                     (1:100)
                                                                                                                                                                                                                           RRID:[AB_262054](https://scicrunch.org/resolver/AB_262054)                         

  Antibody                          Anti-TGFB1,2,3 MAb (Clone 1D11, mouse monoclonal)                                            R and D Systems                                                                           Cat. \# MAB1835\                                                                   (1:50)
                                                                                                                                                                                                                           RRID:[AB_357931](https://scicrunch.org/resolver/AB_357931)                         

  Antibody                          Human Anti-TGFBR2 (goat polyclonal)                                                          R and D Systems                                                                           Cat. \# AF-241                                                                     5 ug/mL

  Antibody                          Donkey Anti-Rabbit Cy5 (rabbit polyclonal)\                                                  Jackson ImmunoResearch                                                                    Cat. \# 711-175-152 RRID:[AB_2340607](https://scicrunch.org/resolver/AB_2340607)   (1:400)

  Antibody                          Strepdavidin Cy5                                                                             Jackson ImmunoResearch                                                                    Cat. \# 016-170-084 RRID:[AB_2337245](https://scicrunch.org/resolver/AB_2337245)   (1:400)

  Antibody                          Anti-phospho- Smad2/3 (rabbit polyclonal)                                                    Cell Signaling                                                                            Cat. \# 8828\                                                                      (1:1000)
                                                                                                                                                                                                                           RRID:[AB_2631089](https://scicrunch.org/resolver/AB_2631089)                       

  Antibody                          Anti-phospho-p38 (rabbit monoclonal)                                                         Cell Signaling                                                                            Cat. \# 4511\                                                                      (1:1000)
                                                                                                                                                                                                                           RRID:[AB_2139682](https://scicrunch.org/resolver/AB_2139682)                       

  Antibody                          Anti-GAPDH (mouse monoclonal)                                                                Millipore Sigma                                                                           Cat. \# MAB374                                                                     (1:1000)

  Antibody                          Goat anti-rabbit IRDye (rabbit polyclonal)                                                   Licor                                                                                     Cat. \# 926--68071\                                                                (1:10,000)
                                                                                                                                                                                                                           RRID:[AB_2721181](https://scicrunch.org/resolver/AB_2721181)                       

  Antibody                          Goat anti-mouse IRDye\                                                                       Licor                                                                                     Cat. \# 926--32210\                                                                (1:10,000)
                                    (mouse polyclonal)                                                                                                                                                                     RRID:[AB_621842](https://scicrunch.org/resolver/AB_621842)                         

  Software, algorithm               ZEN Digital Imaging for Light Microscopy                                                     Zeiss <https://www.zeiss.com/microscopy/int/products/microscope-software/zen-lite.html>   RRID:[SCR_013672](https://scicrunch.org/resolver/SCR_013672)                       

  Software, algorithm               ImageJ                                                                                       ImageJ (<http://imagej.nih.gov/ij/>)                                                      RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)                       

  Software, algorithm               Graphpad Prism                                                                               GraphPad Prism (<https://graphpad.com>)                                                   RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Experimental procedures {#s4-1}
-----------------------

The following mouse lines were used: *Scx-GFP* tendon reporter ([@bib38]), *Scx-CreERT2* (generated by R. Schweitzer), *Acta2-CreERT2* ([@bib17]), ROSA-Ai14 Cre reporter ([@bib30]), and *Tgfbr2^f/f^* ([@bib12]). Lineage tracing and Cre deletion was performed by delivering tamoxifen in corn oil to neonatal mice at P2 and P3 (1.25 mg/pup) ([@bib21]). EdU was given at 0.05 mg 2 hr prior to harvest to label proliferating cells. Global TGFβ inhibition was carried out using the well-established small molecule inhibitor SB-431542 (10 mg/kg in 5% DMSO, intraperitoneal injection) which targets the TGFβ family type I receptors ALK 4/5/7 ([@bib19]; [@bib22]; [@bib26]; [@bib29]; [@bib46]). Daily injections of SB-431542 or carrier were administered from day 0--14 after injury. Full Achilles tendon transection without repair was carried out in neonates at P5, with male and female mice distributed evenly between groups. All procedures were approved by the Institutional Animal Care and Use Committee at Mount Sinai.

Migration assay {#s4-2}
---------------

Neonatal tenocytes were isolated from P7 pups by digestion in 1% collagenase type 1 (Cat. \# LS004188, Worthington, Lakewood, NJ) and collagenase type 4 (Cat. \# LS004188, Worthington, Lakewood, NJ) for 4 hr. Cells were expanded and maintained in high glucose DMEM (Cat. \# 11965092, Life Technologies, [Carlsbad, CA](https://www.google.com/search?rlz=1C1CHBF_enUS708US708&sxsrf=ACYBGNRQnHZTgFNzdi8e-3A2Gf8FgVFwRg:1567995719182&q=Carlsbad,+California&stick=H4sIAAAAAAAAAOPgE-LSz9U3MKmqSInPVeIAsYtMyvO0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcWLWEWcE4tyipMSU3QUnBNzMtPyi_IyEwHsy13aWwAAAA&sa=X&ved=2ahUKEwjrg-ee18LkAhUthOAKHZZNBxYQmxMoATAYegQIDxAL)) with 10% fetal bovine serum (FBS, Life Technologies, [Carlsbad, CA](https://www.google.com/search?rlz=1C1CHBF_enUS708US708&sxsrf=ACYBGNRQnHZTgFNzdi8e-3A2Gf8FgVFwRg:1567995719182&q=Carlsbad,+California&stick=H4sIAAAAAAAAAOPgE-LSz9U3MKmqSInPVeIAsYtMyvO0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcWLWEWcE4tyipMSU3QUnBNzMtPyi_IyEwHsy13aWwAAAA&sa=X&ved=2ahUKEwjrg-ee18LkAhUthOAKHZZNBxYQmxMoATAYegQIDxAL)) and 1% PenStrep (Life Technologies, [Carlsbad, CA](https://www.google.com/search?rlz=1C1CHBF_enUS708US708&sxsrf=ACYBGNRQnHZTgFNzdi8e-3A2Gf8FgVFwRg:1567995719182&q=Carlsbad,+California&stick=H4sIAAAAAAAAAOPgE-LSz9U3MKmqSInPVeIAsYtMyvO0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcWLWEWcE4tyipMSU3QUnBNzMtPyi_IyEwHsy13aWwAAAA&sa=X&ved=2ahUKEwjrg-ee18LkAhUthOAKHZZNBxYQmxMoATAYegQIDxAL)). For the migration assay, cells were serum-starved for 24 hr and then maintained in DMEM only, DMEM+10% FBS, or DMEM+10% FBS+10 ng/mL TGFB1 (Cat. \# 240-B, R and D Systems, Minneapolis, MN). A P200 tip was used scratch down the midline of every well. Phase contrast and fluorescence images were then taken every 4 hr for a total of 12 hr. Cell proliferation was measured by incubating cells with 0.05 mg EdU/well for 30 min prior to harvest. EdU labeling was detected with the Click it EdU kit in accordance with manufacturer's instructions (Cat. \# C10340, Life Technologies, [Carlsbad, CA](https://www.google.com/search?rlz=1C1CHBF_enUS708US708&sxsrf=ACYBGNRQnHZTgFNzdi8e-3A2Gf8FgVFwRg:1567995719182&q=Carlsbad,+California&stick=H4sIAAAAAAAAAOPgE-LSz9U3MKmqSInPVeIAsYtMyvO0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcWLWEWcE4tyipMSU3QUnBNzMtPyi_IyEwHsy13aWwAAAA&sa=X&ved=2ahUKEwjrg-ee18LkAhUthOAKHZZNBxYQmxMoATAYegQIDxAL)).

Whole mount fluorescence imaging {#s4-3}
--------------------------------

Hind limbs were fixed in 4% paraformaldehyde (PFA, Cat. \# 50-980-495, Fisher Scientific, Waltham, MA) overnight at 4°C and skin removed to expose the Achilles tendon. Whole mount images of the posterior limbs were captured using a Leica M165FC stereomicroscope with fluorescence capabilities. Exposure settings were maintained across limbs.

Immunofluorescence and microscopy {#s4-4}
---------------------------------

After sacrifice, limbs were fixed in 4% PFA for 24 hr at 4°C, decalcified in 50 mM EDTA for 1--2 weeks at 4°C, then incubated in 5% sucrose (1 hr) and 30% sucrose (overnight) at 4°C. Limbs were then embedded in optimal cutting temperature medium (Cat. \# 23--730, Fisher Scientific, Waltham, MA) and 12 um transverse cryosections obtained. Immunostaining was carried out with primary antibodies against αSMA (Cat. \# A5228, Sigma, St. Louis, MI), TGFB1,2,3 ligands (Cat. \# MAB1835, R and D Systems, Minneapolis, MN), TGFBR2 (Cat. \# AF-241, R and D Systems, Minneapolis, MN) and secondary detection with antibodies conjugated to Cy5 (Cat. \# 711-175-152; 016-170-084, Jackson ImmunoResearch, West Grove, PA). EdU labeling was detected with the Click it EdU kit in accordance with manufacturer's instructions (Cat. \# C10340, Life Technologies, [Carlsbad, CA](https://www.google.com/search?rlz=1C1CHBF_enUS708US708&sxsrf=ACYBGNRQnHZTgFNzdi8e-3A2Gf8FgVFwRg:1567995719182&q=Carlsbad,+California&stick=H4sIAAAAAAAAAOPgE-LSz9U3MKmqSInPVeIAsYtMyvO0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcWLWEWcE4tyipMSU3QUnBNzMtPyi_IyEwHsy13aWwAAAA&sa=X&ved=2ahUKEwjrg-ee18LkAhUthOAKHZZNBxYQmxMoATAYegQIDxAL)). Fluorescence images were acquired using the Zeiss Axio Imager with optical sectioning by Apotome or using the Leica DMB6 microscope. Cell quantification was performed in Zeiss Zen or Image J software on transverse cryosection images. Immunofluorescence measurements were acquired in ImageJ by measuring average intensity of grayscale images. All images for quantifications were taken at the same exposure and image manipulations applied equally across samples.

RNA isolation, reverse transcription, and qRT-PCR {#s4-5}
-------------------------------------------------

Trizol/chloroform extraction was used to isolate RNA from dissected tendons. cDNA was then synthesized via reverse transcription using the SuperScript VILO master mix (Cat. \# 11755050, Invitrogen, Carlsbad, CA). Gene expression was assessed by qRT-PCR using SYBR PCR Master Mix (Cat. \# 4309155, Thermo Fisher, [Waltham, MA](https://www.google.com/search?rlz=1C1CHBF_enUS708US708&sxsrf=ACYBGNQ9ZGHcG_QPflXkEq4ZaET9XQJSJQ:1567996010780&q=Waltham,+Massachusetts&stick=H4sIAAAAAAAAAOPgE-LSz9U3MCooMTBJU-IAsTOqjE21tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcWLWMXCE3NKMhJzdRR8E4uLE5MzSotTS0qKAbi_f6RdAAAA&sa=X&ved=2ahUKEwiY-eyp2MLkAhXpmOAKHUZ1CysQmxMoATAhegQIChAL)) and calculated using the standard curve method or the 2^--∆∆Ct^ method relative to carrier-treated control tendons. The housekeeping gene, *Gapdh,* was used to normalize gene expression. Primer sequences for TGFβ-related molecules are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. All other primers were previously described ([@bib21]).

Protein extraction {#s4-6}
------------------

Tendons were frozen in liquid nitrogen and pulverized in a Geno/Grinder at 1,500 rpm for 90 s. Pulverized tendons were resuspended in 150 μL T-PER tissue protein extraction reagent (Thermo Scientific, 78510), supplemented with cOmplete protease inhibitor (Roche, 04693159001), and PhosSTOP phosphatase inhibitor (Roche, 4906845001) according to the manufacturer's instructions. To allow for lysis, tendons were rotated end-over-end for 1 hr at 4°C and then ultrasonicated at 10 A for 30 s. Finally, samples were cleared at 10,000 x g for 5 min and the supernatant was collected for western blot analysis and ELISA. Protein concentration was determined using a Bradford assay (Thermo Scientific, PI23238) and a NanoDrop spectrophotometer (Thermo Scientific).

Western blotting {#s4-7}
----------------

Protein extracts were incubated with 5x reducing sodium dodecyl sulfate and polyacrylamide gel electrophoresis (SDS-PAGE) buffer for 5 min at 95°C. Equal volumes of samples were loaded onto 7.5% polyacrylamide gels and separated using a Mini-PROTEAN Tetra Vertical Electrophoresis system (Bio-Rad) at 80 V for 20 min followed by 120 V for 1 hr. After separation of the proteins, gels were transferred to poly-vinylidene difluoride (PVDF) membranes (Immobilon-FL, IPFL00010) using a Mini Trans-Blot Cell (Bio-Rad) at 70 V for 90 min. Following protein transfer, membranes were blocked for 1 hr at RT with 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS). Blots were then incubated with rabbit polyclonal antibody detecting phospho-Smad2/3 (Cell Signaling Technology, 8828), monoclonal antibody detecting phospho-p38 (Cell Signaling Technology, 4511) and a mouse monoclonal GAPDH antibody (Millipore Sigma, MAB374) as loading control, all diluted 1:1000 in 5% BSA in TBS with 0.1% TWEEN-20 (TBS-T) overnight at 4°C. Blots were then washed with TBS-T three times for 5 min and incubated with IRDye 680RD goat anti-rabbit and IRDye 800CW goat anti-mouse secondary antibodies (Licor, 926--68071 and 926--32210) diluted 1:10,000 in 5% BSA in TBS-T for 2 hr at RT. Blots were washed with TBS-T three times for 5 min and TBS for 5 min one time and imaged using the Licor Odyssey imaging system. Fluorescent intensity of individual bands was quantified with ImageJ software and normalized to GAPDH.

ELISA for TGFB1 quantification {#s4-8}
------------------------------

Undiluted protein extracts were assayed with the TGFB1 Quantikine ELISA Kit (R and D Systems, DB100B) according to the manufacturer's instructions. To assess total TGFB1, latent TGFB1 was activated by incubating samples with 1N HCl for 10 min and neutralizing with 1.2N NaOH in 0.5M HEPES. Samples were quantified using a SpectraMax microplate reader and SoftMax Pro software against a standard curve (0--1000 pg/mL TGFβ1).

Gait analysis {#s4-9}
-------------

Mice were gaited at 10 cm/s for 3--4 s using the DigiGait Imaging System (Mouse Specifics Inc, Quincy, MA). A high-speed digital camera was used to capture forelimb paw positions and parameters previously established for mouse Achilles tendon injury were then extracted (Howell+, Sci Rep, 2017). All parameters were normalized to Stride length to account for differences in animal size and age.

Biomechanical testing {#s4-10}
---------------------

Tensile testing was performed in PBS at room temperature using custom 3D printed grips to secure the calcaneus bone and Achilles tendon ([@bib1]). Tendons were preloaded to 0.05N for \~1 min followed by ramp to failure at 1 %/s. Structural properties were recorded; since cross-sectional area could not be accurately measured due to the small size of the tissues, material properties were not analyzed.

Statistical analysis {#s4-11}
--------------------

Quantitative results are presented as mean ± standard deviation. Two way ANOVA was used for comparisons with two independent variables (injury and TGFβ inhibition); where significance was detected, posthoc testing was then carried out (Graphpad Prism). All other quantitative analyses were analyzed using Students t-tests. Significant outliers were detected using Grubb's test (Graphpad Prism). Sample sizes for gait and mechanical properties quantification were calculated from power analyses with power 0.8% and 5% type I error. Samples sizes for other quantitative data were used based on previous data from the lab and published literature. Significance was determined at p\<0.05.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

We appreciate your thoughtful response. The paper represents a novel addition to existing literature on tendon biology. It delineates the molecular basis for neonatal tendon regeneration, And particularly highlights the role of TGFβ signaling. Through a combination of targeted gene deletion, small molecule inhibition, and lineage tracing, the publication identifies TGFβ-dependent and -independent cellular mechanisms involved in tendon regeneration.

**Decision letter after peer review:**

Thank you for submitting your article \"TGFβ signaling is required for tenocyte recruitment and functional neonatal tendon regeneration\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Mone Zaidi as the Reviewing Editor and Clifford Rosen as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Mei Wan (Reviewer \#1); Alayna E Loiselle (Reviewer \#2); Nathanial Dyment (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The studies potentially reveal a new molecular pathway that regulates neonatal tendon regeneration. However, there are several significant concerns with the approach and methodology. The reviewers consider it necessary to validate the labeling specificity of the ScxCreERT2/RosaT mice, document an inhibitory efficiency of the small compound/TβR2 KO on TGFβ signaling; and evaluate cell proliferation.

Essential revisions:

1\) There is a paucity of evidence for pharmacologic and genetic inhibition of the Tgfb pathway, particularly at the dose of the chemical inhibitor that was used. The specificity of labeling in reporter ScxCreERT2/RosaT mice needs further validation, particularly in relation to possible leakiness in the absence of tamoxifen. Exclusion of false positivity is essential. Furthermore, it is unclear whether non-Scx^lin^, ScxGFP+ cells are also labeled by the aSMACreERT2 mouse during the healing process.

2\) Another concern relates to the measurement of functionally active Tgfb, and expressing it as a ratio of total Tgfb. This is because TGFβ is expressed with the latency-associated protein (LAP), rendering it inactive by masking the extracellular matrix (ECM) in many different tissues, including tendons. TGFβ does not have function unless it is activated. Therefore, the mRNA level of TGFβ in tendon tissue (Figure 1) does not reflect the activation of TGFβ signaling. Active TGFβ/ total TGFβ ratio should be measured.

3\) The Westerns showing phosphorylated Smad2/3 need to be replicated and quantitated to establish target engagement and inhibition.

4\) To enhance clarity and firm up conclusions, new data relating to proliferation and migration are required. An in vitro cell proliferation assay is recommended. It is also essential that the authors quantitate proliferating cells and present these as total % of proliferative cells. A scratch assay in parallel to assess migration would be a worthwhile addition. Finally, the authors should examine for migration in TBR2 deficient tenocytes to further support tenocyte-intrinsic effects.

Other points to be addressed:

1\) Tmx labelling should be until \~D7-10 post-injury to confirm that the ScxGFP and ScxAi4 cells overlap, given that the ScxGFP construct has a broader expression pattern than endogenous Scx.

2\) There is a question on whether diminished recruitment of ScxGFP cells also occurs in TβR2^Scx^ mice? This may require more elaborate studies.

3\) The apparent discrepancy between RosaT-labeled cells in Figures 3 and 4 needs to be addressed. \"Little RosaT signal was detected in SB-431542-treated limbs\" in Figure 3B and C and \"few Scx^lin^ tenocytes were detected in TβR2^Scx^ mutant tendons\" in Figure 3F and G. However, there are many red color Scx^lin^ tenocytes were shown in SB-431542-treated (Figure 4B\' and B\') and TβR2^Scx^ mutant tendons. What is the reason for this discrepancy?

4\) In Figure 7, TGFβ ligand were decreased in SB-431542 treated injured mice. The authors concluded that TGFβ signaling is required for upregulation of TGFβ ligands with injury. This conclusion is confusing.

5\) The authors have previously shown insufficient tenocyte recruitment in adult healing, but appropriate recruitment in neonates- is this a function of size/distance since multiple other models show bridging tissue or is this an AT specific finding?

6\) Figure 3D: what do the authors attribute the massive variation in the \# of TdTomato+ cell recruitment in inhibitor treated animals to? These data should also be analyzed as percentage of total cells in the bridging tissue. This will demonstrate whether inhibition affects all cell recruitment or specifically Scx^lin^.

7\) Figure 4: In addition to normalization to carrier and WT for Edu labelling, the total % of proliferative cells would be informative about effects of Tgfb inhibition or deletion on general cellular dynamics.

8\) Supplementary Figure 3/Figure 7: How was intensity of TGFb ligand staining quantified? Since I believe the authors main point is that there are spatial differences it would be appropriate to have these data on the same graph, and to have representative images from the gap space. In addition, what are the two different stains (purple/green) in Figure 7A? Ideally, quantitative analyses of ligand levels via ELISA would be most convincing, but I recognize the technical challenges with this.

9\) TGFb is known to stimulate proliferation of cells in culture. It appears that the cells were not serum starved just prior to the scratch assay or a proliferation inhibitor (e.g., Mitomycin C) was not added in one of the groups. Therefore, it\'s difficult to determine whether the changes were due to migration or proliferation. It would also be a nicer parallel to the in vivo studies to do the scratch assay with the Tgfbr2 cKO cells.

10\) It is recommended not to call aSMA+ cells in this paper only myofibroblasts. Some of them are likely myofibroblasts but not all. Even though aSMA is a marker of a myofibroblast, all mesenchymal cells that express aSMA are not myofibroblasts. aSMA is expressed during expansion of progenitor cell populations that contribute to tissue healing. These cells go on to differentiate into ScxGFP+ cells, osteocytes, fibrocartilage, and odontoblasts. Myofibroblasts, on the other hand, are a more mature cell type. The key defining features of myofibroblasts are the de novo development of in vivo stress fibers and contractile forces. Stress fibers containing aSMA produce higher contractile forces, which is why myofibroblasts express aSMA. The fact that aSMA expression was not inhibited at this early stage by SB-431542, despite TGFb being a potent inducer of myofibroblasts (as stated in the third paragraph of the Discussion), also indicates that these cells may not be myofibroblasts.

11\) It is suggested that the authors add uninjured limbs to the main figure instead of in Figure 2---figure supplement 1. Panels A and B have the uninjured limbs so it would balance the figure nicely.

12\) Figure 4C -- it would help to indicate on the graph that proliferation of the Scx^lin^ cells is reported.

13\) Figure 6---figure supplement 1 -- Was aSMA staining higher at D14 in SB-431542-treated group? This could further support that healing is diminished/delayed in the treated group.

14\) The titles of Figures 7 and 8 are the same.
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Author response

> Essential revisions:
>
> 1\) There is a paucity of evidence for pharmacologic and genetic inhibition of the Tgfb pathway, particularly at the dose of the chemical inhibitor that was used. The specificity of labeling in reporter ScxCreERT2/RosaT mice needs further validation, particularly in relation to possible leakiness in the absence of tamoxifen. Exclusion of false positivity is essential.

Pharmacologic inhibition

SB-431542 is a very well established TGFβ inhibitor used in many in vivo mouse studies at doses ranging from 0.17 mg/kg to 10mg/kg, with various injection regimens such as oral gavage, single IP injection, or daily IP injection (see references listed at end of response: (Alyoussef, 2018; Araujo-Jorge et al., 2012; Bayomi et al., 2013; Chowdhury et al., 2015; Koh et al., 2015; Lemos et al., 2015; Lu et al., 2018; Mercado-Gomez et al., 2014; Miao et al., 2014; Mohamed et al., 2017; Mordasky Markell et al., 2010; Pulli et al., 2015; Sato et al., 2015; Schindeler et al., 2010; Shi et al., 2017; Tanaka et al., 2010; Waghabi et al., 2007; Wei et al., 2010; Zhang et al., 2016; Zhou et al., 2019)). We chose our dosing regimen based on this prior literature and used 10 mg/kg daily IP injections as the most commonly used, highest dose, and therefore most likely to be effective. To determine the effect of the drug on TGFβ signaling, we carried out western blotting for pSmad2/3 with carrier and SB-431542 treatment. We were surprised not to see a difference between injured tendons (carrier vs. inhibitor), however there was a significance increase in uninjured control tendons with inhibition. This suggested that the systemic level of pSmad2/3 is generally higher in those mice and we therefore normalized to the contralateral control. Once normalized, there was a \~67% reduction in pSmad2/3 with SB-431542 treatment (new Figure 2---figure supplement 1).

This difference in pSmad2/3 in control tendons could indicate a potential feedback mechanism with SB-431542 inhibition or potential compensation by other TGFβ superfamily molecules. We also tested whether this result was specific to pSmad2/3 by assaying phospho-p38 protein (a non-Smad mediator of TGFβ signaling) and found no difference with injury or with inhibitor treatment, either normalized or un-normalized. This is expected as SB-431542 should not affect ERK or p38 signaling, based on in vitro studies (see (Inman et al., 2002). There is also a question of whether we chose the right time (2 hours after last injection) to harvest the tendons. There is evidence that TGFβ signaling is cyclic (Zi et al., 2012); the compound may therefore only inhibit at certain durations per day. Although our pSmad2/3 results were somewhat unexpected, we do see a relative inhibition with SB-431542 and many of our results (the functional assays, recruitment, total cells) point to an effect of the inhibitor on healing. Materials and methods, Results subsection "TGFβ signaling is required for functional regeneration", and Discussion have been updated with a new Figure 2---figure supplement 1.

Genetic deletion

The original Tgfbr2^Scx^ samples were extremely hard to come by. We lost many litters (representing perhaps \~200 mice) after tamoxifen treatment and the samples included here were the few that survived. Outcrossing the line did not help (we tried twice) and after years of attempted experiments, we eliminated the line in early 2019, prior to the initial submission of this manuscript. While we were therefore not able to generate new mice for experiments, we examined remaining cryosections and tried immunostaining for pSmad2/3 (did not work) and immunostaining for TGFBR2. We now include the TGFBR2 results showing reduced immunostaining of TGFBR2 in Tgfbr2^Scx^ mutants with tamoxifen treatment (new Figure 3---figure supplement 2, subsection "TGFβ signaling in neonatal tenocytes is required for cell recruitment after injury").

> The specificity of labeling in reporter ScxCreERT2/RosaT mice needs further validation, particularly in relation to possible leakiness in the absence of tamoxifen.

Analysis of ScxCreERT2/RosaT/ScxGFP mice at 1 year of age without any tamoxifen injections showed no presence of RosaT+ cells suggesting that there is no leakiness. We chose the oldest age maintained in our colony to span the widest range of time for leakiness to possibly occur. This is now included as Figure 3---figure supplement 1 (subsection "TGFβ signaling in neonatal tenocytes is required for cell recruitment after injury".

> Furthermore, it is unclear whether non-Scx^lin^, ScxGFP+ cells are also labeled by the aSMACreERT2 mouse during the healing process.

This is a very interesting point. To truly address this, we would likely need to lineage trace both Scx^lin^ and aSMA^lin^ cells within the same mouse, which is currently impossible since these are both CreERT2 lines. However, if all ScxGFP cells are from the aSMA^lin^, this would point to the epitenon/paratenon as a likely second source of cells. To test this, we generated aSMACreERT2/RosaT/ScxGFP pups with P2, P3 tamoxifen labeling and P5 injury, with and without injection of SB-431542 (n=2/group although 1 mouse ended up ScxGFP-negative in the untreated group and was not useful). All pups at d14 showed recruitment of RosaT+ cells into the gap space, regardless of SB-431542 treatment. This is consistent with our aSMA immunostaining showing that aSMA cells were not affected by SB-431542 treatment at d3. We found aSMA^lin^ cells comprised a majority of non-ScxGFP cells and a proportion (but not all) of ScxGFP+ cells (new Figure 8---figure supplement 3). Since aSMA labels some of the original tenocytes (Figure 8---figure supplement 2) we still cannot completely exclude the possibility that aSMA^lin^+/ScxGFP+ cells are also Scx^lin^. The Results and Discussion have been revised accordingly with new Figure 8---figure supplement 3. (See subsection "Non-Scx^lin^ tenogenic cells also contribute to neotendon formation" and Discussion).

> 2\) Another concern relates to the measurement of functionally active Tgfb, and expressing it as a ratio of total Tgfb. This is because TGFβ is expressed with the latency-associated protein (LAP), rendering it inactive by masking the extracellular matrix (ECM) in many different tissues, including tendons. TGFβ does not have function unless it is activated. Therefore, the mRNA level of TGFβ in tendon tissue (Figure 1) does not reflect the activation of TGFβ signaling. Active TGFβ/ total TGFβ ratio should be measured.

We measured active and latent TGFβ1 using ELISA and show increased levels of total TGFβ1 with injury and no change in active TGFβ1. Although it was long thought that TGFβ cannot signal without release from the latent complex, an interesting paper in Cell recently showed that latent TGFβ may also be able to signal by binding through the integrin αvβ8 (Campbell et al., 2020). It is also possible that most of the signaling is mediated by TGFβ3, which we were not able to assay since the mouse TGFβ2 and TGFβ3 ELISA kits are either not commercially available or not validated for tissue lysates (as discussed with the manufacturer for the TGFβ3 kit). We do identify increases in pSmad2/3 signaling however, which indicates active signaling with injury. We now include this Cell reference and updated Materials and methods, Results subsection "TGFβ signaling is activated after neonatal injury", and Discussion.

> 3\) The Westerns showing phosphorylated Smad2/3 need to be replicated and quantitated to establish target engagement and inhibition.

Western blots for pSmad2/3 are now included using newly collected samples and quantified as requested (updated Figure 1, subsection "TGFβ signaling is activated after neonatal injury").

> 4\) To enhance clarity and firm up conclusions, new data relating to proliferation and migration are required. An in vitro cell proliferation assay is recommended. It is also essential that the authors quantitate proliferating cells and present these as total % of proliferative cells. A scratch assay in parallel to assess migration would be a worthwhile addition.

We agree with the reviewer that the proliferative effects of TGFβ may complicate our interpretation of the scratch assay. First, the cells were indeed serum-starved prior to the assay and the methods are now updated to reflect this (we apologize for omission). However, EdU staining did show some degree of proliferation occurred despite serum-starving. Therefore, we now include the requested experiment repeating the scratch assay and quantifying proliferation to determine whether proliferation and migration were in any way coupled. Our results show enhanced gap space closure with the addition of TGFβ1 without a significant difference in proliferation (updated Figure 5, subsection "TGFβ signaling is required for tenocyte migration but not proliferation").

> Finally, the authors should examine for migration in TBR2 deficient tenocytes to further support tenocyte-intrinsic effects.

As explained above, the Tgfbr2 floxed line is no longer available in our colony. To determine tenocyte intrinsic effects in the culture model, we therefore labeled cells using ScxCreERT2 and analyzed the behavior of the labeled cells in the dish. Quantification showed enhanced migration capacity of Scx^lin^ cells in the presence of TGFβ1 (updated Figure 5, subsection "TGFβ signaling is required for tenocyte migration but not proliferation").

> Other points to be addressed:
>
> 1\) Tmx labelling should be until \~D7-10 post-injury to confirm that the ScxGFP and ScxAi4 cells overlap, given that the ScxGFP construct has a broader expression pattern than endogenous Scx.

We were not able to carry out this experiment due to lab closure, but the broader expression pattern of ScxGFP is an excellent and important point; we have now included this as a Discussion point. This may also reflect incomplete recombination (although we do see \~96% of ScxGFP+ tenocytes in the contralateral control tendon is recombined).

> 2\) There is a question on whether diminished recruitment of ScxGFP cells also occurs in TβR2^Scx^ mice? This may require more elaborate studies.

Unfortunately, many of the Tgfbr2^Scx^ samples collected did not have ScxGFP (this includes all of the d14 samples). We had 2 mutant samples collected at d28 (which were not included in the original manuscript) that showed the presence of ScxGFP cells despite minimal Scx^lin^ cell recruitment. Given our new results with aSMACreERT2, it is likely this population (at least in part) comes from aSMA^lin^ cells. This is now included as Figure 8---figure supplement 1 and the Results subsection "Non-Scx^lin^ tenogenic cells also contribute to neotendon formation" revised.

> 3\) The apparent discrepancy between RosaT-labeled cells in Figures 3 and 4 needs to be addressed. \"Little RosaT signal was detected in SB-431542-treated limbs\" in Figure 3B and C and \"few Scx^lin^ tenocytes were detected in TβR2^Scx^ mutant tendons\" in Figure 3F and G. However, there are many red color Scx^lin^ tenocytes were shown in SB-431542-treated (Figure 4B\' and B\') and TβR2^Scx^ mutant tendons. What is the reason for this discrepancy?

Figure 4 showed a section at the injured edge of the tendon stub at d3 where we see the original tenocytes (highly labeled) proliferating at d3. Figure 3 is from the midsubstance (former gap space) at d14 where we quantify recruitment (all labeled cells here would have had to migrate into the space). We have clarified this in the revised text (adding 'midsubstance region' and 'injured tendon edge' to describe locations of transverse sections (subsection "TGFβ signaling in neonatal tenocytes is required for cell recruitment after injury".

> 4\) In Figure 7, TGFβ ligand were decreased in SB-431542 treated injured mice. The authors concluded that TGFβ signaling is required for upregulation of TGFβ ligands with injury. This conclusion is confusing.

It is decreased relative to the carrier injured group but not to the non-injured controls. We interpret this to mean that normally after injury, there is an increase in TGFβ ligands at d3 at the cut site. With TGFβ inhibition, the increase is not observed (the SB-431542 injured group is not different from the carrier or SB-431542 non-injured groups). While it would also be helpful to have TGFβ1 ELISA data from the inhibitor treated cohort at d3 to support these data, we were not able to generate additional mice at this time. In addition, since the increase is specific to a localized region of the tendon, it is not clear the difference would be detectable since whole tendon lysates are combined and used for ELISA.

> 5\) The authors have previously shown insufficient tenocyte recruitment in adult healing, but appropriate recruitment in neonates- is this a function of size/distance since multiple other models show bridging tissue or is this an AT specific finding?

We measured the gap space normalized to the original geometry of the contralateral tendon and found there is no difference in relative gap space between neonates and adults (indeed, relative gap space normalized to length may be slightly larger in neonates). Since the current study does not include adult injury, we only show these data as [Author response image 1](#respfig1){ref-type="fig"}. We posit that the transection injury without repair creates a critical size defect in adults and adult tenocytes are not able to bridge this gap while neonatal tenocytes are able. Elegant studies from Dr. Loiselle's lab observed successful bridging of adult tenocytes of flexor tendons when tendon ends are sutured, suggesting there may be a gap distance threshold for adult tenocyte recruitment. Note that although the adult gap space is not occupied by Scx^lin^ tenocytes, there IS bridging fibrovascular scar tissue that is highly aSMA+ at d14. There may also be tendon-specific differences as suggested by reviewers, since work from Dr. Dyment previously showed that the patellar tendon defect is bridged by paratenon cells without significant activity of the intrinsic tenocytes (in this model however, full transection was not carried out). Single cell RNASeq data from Dr. Chris Mendias's group also show significant transcriptional differences between specific mouse tendons; these differences may result in different healing responses. Since this manuscript does not include any data from adult injury, we do not include extensive discussion of these points related to adult tendon injury models, but hopefully this response addresses reviewers' questions.

![](elife-51779-resp-fig1){#respfig1}

> 6\) Figure 3D: what do the authors attribute the massive variation in the \# of TdTomato+ cell recruitment in inhibitor treated animals to? These data should also be analyzed as percentage of total cells in the bridging tissue. This will demonstrate whether inhibition affects all cell recruitment or specifically Scx^lin^.

To determine whether this variation is due to a single outlier or natural variability in healing, we acquired more ScxCreERT2/RosaT mice (n=2 Carrier and n=1 SB-431542). While the difference between treatment groups is now significant (p\<0.05), the variability in the Carrier treated group remains. We therefore believe this is simply due to natural biological variation in the healing process. New graphs representing recruitment as percentage is also now included and we thank the reviewers for this suggestion. Interestingly, we find that total DAPI cells is decreased with SB-431542 treatment and Scx^lin^ cell recruitment is no longer different once normalized. However, no difference in total DAPI was observed in TBR2 group vs. WT and normalized Scx^lin^ recruitment is still different. This suggests to us that in the Tgfbr2 mutants, there is compensatory recruitment of non-Scx^lin^ cells when Scx^lin^ cells are not recruited. With SB-431542 treatment however, the compensation does not happen and total DAPI is reduced. We have now updated the Results subsection ",TGFβ signaling in neonatal tenocytes is required for cell recruitment after injury", Discussion, and Figure 3.

> 7\) Figure 4: In addition to normalization to carrier and WT for Edu labelling, the total % of proliferative cells would be informative about effects of Tgfb inhibition or deletion on general cellular dynamics.

The requested data are now included. The new data suggests that while Scx^lin^ cell proliferation is not affected with SB-431542 treatment, proliferation of non-Scx^lin^ cells may be decreased at d3 (p=0.07) while Tgfbr2^Scx^ mutants are not affected. Combined with our new results for DAPI quantification at d14, this suggests that the reduction in non-Scx^lin^ cells at d14 may stem in part from reduced proliferation at the earlier stage. Results subsection "TGFβ signaling is required for tenocyte migration but not proliferation" and Figure 4 have been updated.

> 8\) Supplementary Figure 3/Figure 7: How was intensity of TGFb ligand staining quantified? Since I believe the authors main point is that there are spatial differences it would be appropriate to have these data on the same graph, and to have representative images from the gap space. In addition, what are the two different stains (purple/green) in 7A? Ideally, quantitative analyses of ligand levels via ELISA would be most convincing, but I recognize the technical challenges with this.

Staining intensity was quantified in ImageJ to obtain mean intensity in a region of interest. In tendons, the region of interest was chosen based on ScxGFP signal. In the gap space where there is no ScxGFP signal at d3, the region of interest was selected based on DAPI. The images have now been updated to show representative selected regions. As suggested by the reviewers, we now include data in the same graph and representative images from the gap space are now included (updated Figure 7). The green (ScxGFP) and purple (TGFβ1,2,3) signals are also now clearly labeled.

We also provide ELISA results for d14 for active TGFβ1 in Figure 7. We wish we were able to assay total TGFβ1 as well for this but did not have enough protein left. (See Results subsection "Increased TGFβ ligand production in injured tendon depends on TGFβ signaling").

> 9\) TGFb is known to stimulate proliferation of cells in culture. It appears that the cells were not serum starved just prior to the scratch assay or a proliferation inhibitor (e.g., Mitomycin C) was not added in one of the groups. Therefore, it\'s difficult to determine whether the changes were due to migration or proliferation. It would also be a nicer parallel to the in vivo studies to do the scratch assay with the Tgfbr2 cKO cells.

Cells were serum-starved prior to scratch assay. We apologize this detail was missing from the Materials and methods (now included). We have now repeated this experiment and included EdU quantification of proliferation during the scratch assay. Since we no longer have the Tgfbr2 floxed line, we are unable to carry out the experiment recommended. However, to distinguish tenocyte vs. non-tenocyte/epitenon migration/proliferation, we include ScxCreERT2 labeling in the assay and have quantified these cells. Note that Scx^lin^ cells were labeled in vivo at P2, P3 as normal and non-injured tendons harvested at P7 for the culture assay. The Materials and methods, Results subsection "TGFβ signaling is required for tenocyte migration but not proliferation", and Figure 5 have been updated.

> 10\) It is recommended not to call aSMA+ cells in this paper only myofibroblasts. Some of them are likely myofibroblasts but not all. Even though aSMA is a marker of a myofibroblast, all mesenchymal cells that express aSMA are not myofibroblasts. aSMA is expressed during expansion of progenitor cell populations that contribute to tissue healing. These cells go on to differentiate into ScxGFP+ cells, osteocytes, fibrocartilage, and odontoblasts. Myofibroblasts, on the other hand, are a more mature cell type. The key defining features of myofibroblasts are the de novo development of in vivo stress fibers and contractile forces. Stress fibers containing aSMA produce higher contractile forces, which is why myofibroblasts express aSMA. The fact that aSMA expression was not inhibited at this early stage by SB-431542, despite TGFb being a potent inducer of myofibroblasts (as stated in the third paragraph of the Discussion), also indicates that these cells may not be myofibroblasts.

This is a critical point and we agree completely. The language has been modified throughout the text, the discussion on myofibroblasts removed, and new discussion on aSMA^lin^ cells included (Discussion).

> 11\) It is suggested that the authors add uninjured limbs to the main figure instead of in Figure 2---figure supplement 1. Panels A and B have the uninjured limbs so it would balance the figure nicely.

The uninjured limbs have been added to Figure 2.

> 12\) Figure 4C -- it would help to indicate on the graph that proliferation of the Scx^lin^ cells is reported.

The graph has been updated as recommended.

> 13\) Figure 6---figure supplement 1 -- Was aSMA staining higher at D14 in SB-431542-treated group? This could further support that healing is diminished/delayed in the treated group.

We returned to our images and quantified the staining using DAPI to select the region of interest. To our surprise, we do find that there is a difference in the SB-431542 treated group. We also quantified aSMA staining for Tgfbr2^Scx^ mutants at d14 and found no difference. This is now included in the text and updated Figure 6---figure supplement 1, we thank the reviewers for this suggestion (subsection "Non-Scx^lin^ tenogenic cells also contribute to neotendon formation").

> 14\) The titles of Figures 7 and 8 are the same.

The title for Figure 8 has been corrected, thank you (subsection "Non-Scx^lin^ tenogenic cells also contribute to neotendon formation").
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